NEWS & EVENTS

NEWS

SpikImm announces the appointment of Bruno Lucidi to its Board of Directors, effective June 1, 2026.

An international biopharmaceutical leader with extensive experience in drug discovery, corporate strategy, and biotech company development, Bruno Lucidi brings a strong track record from senior roles at Bristol Myers Squibb, Johnson & Johnson, GlaxoSmithKline, Mink Therapeutics, Karolinska Development, Aprea, Pharmasset, and Idenix Pharmaceuticals.

His expertise in infectious diseases, immunology, oncology, and global biotech strategy will support SpikImm as the company advances its next-generation monoclonal antibodies against viral infections, including BK virus reactivation in transplant patients and future pandemic threats.

Recent reports of Hantavirus infections involving human-to-human transmission highlight the importance of strengthening our armamentarium against potential viral threats.

SpikImm will be attending #BIOEuropeSpring

Spikimm will be participating to Basel for the health.tech | global summit (March 3–5, 2026).

SpikImm will participate in the 44th Annual J.P. Morgan Healthcare Conference (January 12–15, 2026) in San Francisco.

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

SPIKIMM receives 15 Million Euros in non-dilutive funding awarded by France 2030 to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-COV-2

SPIKIMM, a biotech company founded by Truffle Capital and Institut Pasteur, announce that SPK001, its monoclonal antibody has demonstrated a potent and broad neutralization activity across all SARS-COV-2 variants of concern, including Omicron (BA.1 AND BA.2)

Coronavirus variants are dodging antibody treatments. New lab-made options may help

Long-term benefits of clean energy sources

SpikImm announces the signature of an exclusive license option and
collaboration agreement with SATT Conectus

France 2030 : la recherche et l’innovation au cœur des enjeux pour prévenir et lutter contre les maladies infectieuses émergentes et les menaces nucléaire, radiologique, biologique et chimique

SPIKIMM, a biotechnology company founded by Truffle Capital under license from the Institut Pasteur, announces that the clinical trials for SPK001, its monoclonal antibody against SARS-COV-2, have begun

‘Super-antibodies’ could curb COVID-19 and help avert future pandemics

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

Creation of the startup SPIKIMM to develop monoclonal antibodies as an innovative treatment for Covid-19